文献速递神经肿瘤

42例巨大脑膜瘤队列的复发率与死亡率

Recurrence and Mortality Rate in a 42 Patient Cohort of Giant Meningiomas.
PubMed 文献 · World Neurosurg · 2024-04-01

回顾性分析2012年12月至2022年1月42例至少一个维度≥5 cm的巨大脑膜瘤患者,平均随访27.19±29.87个月,复发5例(11.9%),死亡率为11.9%,复发组世界卫生组织2级肿瘤数量(P=0.013)和肿瘤大小(P=0.006)显著更高,复发组死亡率显著更高(P=0.025)。

要点

  • 42例巨大脑膜瘤患者中复发5例(11.9%),死亡率为11.9%。
  • 复发组世界卫生组织2级肿瘤数量显著更高(P=0.013)。
  • 复发组肿瘤大小显著更大(P=0.006),且复发组死亡率显著更高(P=0.025)。

核心结论

  • 巨大颅内脑膜瘤因手术经验、肿瘤大小、瘤周水肿、血供、解剖改变和视野受限而具有挑战性,复发和死亡风险高。

研究设计与样本

  • 回顾性分析2012年12月至2022年1月间影像学检查显示任意平面至少一个维度≥5 cm的脑膜瘤患者的医疗档案,肿瘤尺寸在磁共振图像上测量(1例除外),除2例外所有患者均进行临床随访,平均随访27.19±29.87个月(范围4-112个月),共42例患者。

主要发现

  • 42例患者中女性26例(61.9%),男性16例(38.1%),年龄31至85岁(平均60.31±14.86岁)。
  • 头痛(57.1%)是最常见症状,平均肿瘤大小70.14±19.03 mm(范围50-152 mm),肿瘤最常位于额部凸面(40.5%)。
  • 辛普森I级切除占19%,世界卫生组织1级肿瘤占74%,2级占26%,主要并发症发生在26.1%的患者中。
  • 复发5例(11.9%),复发组世界卫生组织2级肿瘤数量显著更高(P=0.013),肿瘤大小显著更大(P=0.006)。
  • 死亡率为11.9%,复发组死亡率显著更高(P=0.025)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Giant meningiomas may show special features in terms of biological behavior and management. We aimed to research recurrence and mortality of giant meningiomas. METHODS: Medical files of patients with meningioma with at least 1 dimension of ≥5 cm in any plane in radiological investigations between December 2012 and January 2022 were retrospectively reviewed. Tumor dimensions were measured on magnetic resonance images except 1. All patients except two underwent clinical follow-up at a mean of 27.19 ± 29.87 (range, 4-112) months. RESULTS: There were 42 patients, 26 (61.9%) women and 16 (38.1%) men who ranged in age from 31 to 85 (mean, 60.31 ± 14.86) years. Headache (57.1%) was the most common symptom. The mean tumor size was 70.14 ± 19.03 (range, 50-152) mm. Tumors were most located at the frontal convexity (40.5%). Simpson grade I resection was achieved in 19% of the cases. The tumors were World Health Organization grade 1 in 74% and grade 2 in 26% of the cases. Major complications developed in 26.1% of the patients. Recurrence happened in 5 (11.9%) cases. The number of World Health Organization grade 2 tumors (P = 0.013; P < 0.05) and tumor size (P = 0.006; P < 0.01) were significantly higher in the recurrent cases. Mortality was % 11.9 and statistically significantly higher in the recurrence group (P = 0.025; P < 0.05). CONCLUSIONS: Giant intracranial meningiomas are challenging because of surgical experience, tumor size, peritumoral edema, blood supply, anatomical changes, and limited visibility. They have a high risk of recurrence and mortality.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Demiraslan A, Çelikoğlu E, Hakan T, et al. Recurrence and Mortality Rate in a 42 Patient Cohort of Giant Meningiomas. World Neurosurg. 2024. PMID: 38570092. doi:10.1016/j.wneu.2024.03.133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。